

**IN THE SPECIFICATION:**

Please amend the paragraph at page 3, lines 20-27 as follows:

The present invention additionally relates to an antibody which binds selectively to CDT, where the binding takes place in the region of the following segments (SEQ ID NOS: 1-4) ~~(1) to (4)~~ of the CDT sequence:

SEQ ID NO: (1)    VVARSMGGKEDLIWELL                      and  
SEQ ID NO: (2)    TTEDSIAKIMNGEADAMSLDGGF                      and  
SEQ ID NO: (3)    SKLSMGSGNLNLSEPN                      and  
SEQ ID NO: (4)    YEKYLGEELYVKAV.

Please amend the paragraph at page 5, lines 21-35 as follows:

The present invention further relates to a process for preparing an ~~the~~ antibody by immunizing a suitable experimental animal with unglycosylated transferrin or CDT, subsequently fusing the spleen cells of this experimental animal to myeloma cells, resulting in antibody-producing hybrid cells, and subsequently cloning the hybrid cells and selecting a hybrid cell clone which produces an antibody whose binding according to the results of an epitope mapping takes place in the region of the following segments (SEQ ID NOS:1-4) ~~(1) to (4)~~ of a CDT sequence:

SEQ ID NO: (1)    VVARSMGGKEDLIWELL                      and  
SEQ ID NO: (2)    TTEDSIAKIMNGEADAMSLDGGF                      and  
SEQ ID NO: (3)    SKLSMGSGNLNLSEPN                      and  
SEQ ID NO: (4)    YEKYLGEELYVKAV;

followed finally by the obtaining of antibodies by a process known to the skilled worker from the hybrid cell clone selected in this way.

Please amend the paragraph at page 21, lines 6-23, as follows:

After evaluation of the investigation, the binding peptides for the prior art antibodies are revealed to be the following dominant segments of SEQ ID NO: 5 and SEQ ID NO: 6 as follows:

Prior art antibodies against peptide 1 (SEQ ID NO: 5)

1. VLAENYNKSDNCE
2. AENYNKSDNCEDT
3. NYNKSDNCEDTPE
4. NKSDNCEDTPEAG

Prior art antibodies against peptide 2 (SEQ ID NO: 6)

1. VHKILRQQQHLFG
2. KILRQQQHLFGSN
3. LRQQQHLFGSNVT
4. QQQHLFGSNVTDC
5. QHLFGSNVTDCSG

Please amend the paragraph at page 21, line 28 to page 22, line 5 as follows:

The antibody 98-84/011 of the invention reacts with ~~four~~ a dominant segments of each of SEQ ID NOS: 1-4. the sequence:

SEQ ID NO: 1

1. VVAR**SMGGKEDLI**
2. AR**SMGGKEDLIWE**
3. **SMGGKEDLIWELL**

SEQ ID NO: 2

4. TTED**SIAKIMNGE**
5. **SIAKIMNGEADAM**
6. **AKIMNGEADAMSL**
7. **IMNGEADAMSLDG**
8. **NGEADAMSLDGGF**

SEQ ID NO: 3

9. **SKLSMGSGGLNLSE**
10. **LSMGSGGLNLSEPN**

SEQ ID NO: 4

11. **YEKYLGEELYVKAV**

FINNEGAN  
ENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)